Extended Data Fig. 1: Combining MCSP immunofluorescence with melanoma transcript and genome analysis identifies melanoma DCCs.
a, Schematic overview of analyzed patient samples, drop-out causes and reference to individual figure panels. Number of patients, SLNs and cells are depicted in black, red and blue, respectively. b, Staining intensity of MCSP+ cells in SLNs and LNs of melanoma and nonmelanoma patients. Scale bar as indicated. See also Fig. 1c for merged images of fluorescence and bright field channels of MCSP+ cells in SLNs of melanoma patients. c, Percentage of MCSP+ SLNs of melanoma patients with MCSP+ cells separated according to their phenotype (diameter) into small (S), small and large (S + L), large (L) cells. SLN numbers see panel a) and main text. d, Percentage of gp100-MCSP+ (n = 275) and gp100+MCSP- SLN (n = 17) among SLNs of melanoma patients with staining-results for both gp100 and MCSP (n = 542). gp100-MCSP+ SLNs are annotated according to the observed phenotype (diameter) of detected MCSP+ cells. e, Percentage of MCSP+ small (n = 789) and large (n = 237) cells negative or positive for MT expression (gp100, DCT and MLANA), either alone (single+) or in combination (double+ for any two markers or triple+). f, Percentage of MCSP+MT- cells with or without CD45 expression isolated from melanoma (MT- small cells, n = 715) and nonmelanoma patients (MT- small cells, n = 61), MT = melanoma transcripts. g, Cumulative frequency plots of genomic aberrations in MCSP+MT+CD45- large (n = 13) and small (n = 15) cells with genomic gains and losses in orange and blue, respectively.
